ASH 2023 | BMT CTN 1506/MORPHO: FLT3-ITD variant allele frequency and MRD data
Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses a post-hoc analysis of measurable residual disease (MRD) from the BMT CTN 1506/MORPHO study (NCT02997202) of gilteritinib in patients with FLT3-ITD mutated acute myeloid leukemia (AML). Dr Levis outlines the findings regarding FLT3-ITD variant allele frequency and how this relates to survival of patients, and highlights that a previously unknown aspect of AML disease biology was uncovered through this study. A unique quantitative assay was also specifically designed for measuring MRD in this trial. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: FujiFilm, Astellas Global Pharma
Consultancy: Takeda, Menarini, Jazz, Daiichi-Sankyo, Bristol Myers Squibb, Amgen, Abbvie, Pfizer
